Fundraising FoxJJDC
Venture capitalNew Brunswick · Seed–Series B · 11 people tracked
Find your way into JJDC
Each arrow is one introduction. Sign up to fill in the first one.
Ask Chris Picariello to introduce you to Tamir Meiri
You →Chris · together at Johnson & Johnson Innovation – JJDC →Tamir
Ask Jamie Chen to introduce you to Asish K. Xavier
You →Jamie · together at Arialys Therapeutics →Asish
Ask Sam Okafor to introduce you to Marian Nakada
You →Sam · together at Navitor Pharmaceuticals →Marian
Sign up to find every way you can get introduced to JJDC
- Your email: who you already know at JJDC, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the JJDC team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
JJDC is the venture capital arm of Johnson & Johnson, investing since 1973 across medical devices, diagnostics, pharmaceuticals, and consumer health. The firm provides seed through late-stage venture financing to companies whose technologies and business models align with Johnson & Johnson's strategic interests.
Team · 11 people
from public directoriesWhat they invest in
from 13 of 14 portfolio companiesHealthtech ×10Biotech ×9AI & Machine Learning ×2Digital Health ×2Medical Devices ×2Data & Infrastructure ×1Deep Tech ×1Longevity ×1
HQs:United States×7China×1United Kingdom×1
Investments · 14 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 22024 · 12022 · 12019 · 22017 · 12016 · 12015 · 110 dated
Contineum is a biopharmaceutical company developing small molecule drug candidates to treat inflammatory and fibrotic diseases by modulating critical disease pathways.
BiotechHealthtech
Carmine Stengone(President and Chief Executive Officer)inPeter T. Slover(Chief Financial Officer)inDaniel S. Lorrain(Chief Scientific Officer)inTimothy R. Watkins(Chief Medical Officer and Head of Development)in
Co-investorsHadean VenturesRed Tree VentureSamsara BioCapitalCasdin CapitalFranklin TempletonSectoral Asset Management+1 more
Protagonist is a company that emphasizes a diverse and inclusive corporate culture as central to its innovation, with stated goals of creating wins for its organization and for patients.
BiotechHealthtechMilpitas, US
Dinesh V. Patel, PhD(Executive Officer, Director)Dinesh Patel(President & Chief Executive Officer)
BoardAsish K. Xavier, Ph.D.(Director)Michael Panaccio, Ph.D.(Director)Armen Shanafelt, Ph.D.(Director)Paul F. Truex(Director)
Co-investorsAisling CapitalCanaan PartnersJohnson & Johnson Innovation – JJDCLilly VenturesRA CapitalStarfish Ventures
Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.
BiotechHealthtechLongevity
Co-investorsAtlas VentureDroia VenturesEcoR1 CapitalGV (Google Ventures)The Column GroupAbbVie+3 more
Healthcare technology company delivering real-world evidence for life sciences companies, payers, and regulators.
Data & InfrastructureDigital HealthHealthtechNew York, US
Sebastian G. Schneeweiss(Director)William Geary(Director)inJeremy Rassen(Founder)Kyle Armbrester(Chief Executive Officer)inSebastian Schneeweiss(Founder)
Co-investorsB Capital GroupB4 CapitalBlue LionBlue Lion GlobalFlare Capital PartnersForesite Capital+8 more
.jpeg){kind=logo}
BrainsGate develops a neurostimulation therapy for stroke patients based on stimulation of the sphenopalatine ganglion (SPG) to increase cerebral blood flow.
BiotechHealthtechMedical Devices
Co-investorsAgate Medical Investments LPCipio PartnersElron VenturesPitangoSpero Ventures
Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.
BiotechHealthtech
John Valliant(Founder)in
Co-investorsFACIT (Fight Against Cancer Innovation Trust)HealthCapLumira VenturesPivotal Life SciencesSeroba Life SciencesVenture Ontario+6 more
Mestag is an immunology company developing first-in-class treatments for cancer and inflammatory diseases by leveraging novel understanding of fibroblast biology and tertiary lymphoid structures.
AI & Machine LearningBiotechDigital HealthHealthtechLondon, GB
Michael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)inSoumya Raychaudhuri(Founder)David A. Tuveson(Founder)Lindsey Rolfe(Chief Medical Officer)in
Co-investorsGV (Google Ventures)SV Health InvestorsForbionJohnson & Johnson Innovation – JJDCNorthpond Ventures
Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets.
AI & Machine LearningBiotechDeep Tech
Co-investorsM VenturesOxford Science EnterprisesPfizer Venture InvestmentsBritish Patient CapitalPfizer Ventures
Developing novel KRAS degraders.
Burlington, US
Huaixiang Hao(Founder)in
Co-investorsMRL Ventures FundBioTrack Capital
BiotechLexington, US
Victoria M. Richon(Executive Officer, Director)in
BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)
Co-investorsAvego BioScience CapitalOUP (Osage University Partners)Peregrine VenturesAbbVieDeerfield Management CompanyNovartis Venture Fund+4 more
HealthtechCambridge, US
Adam Rosenberg(Executive Officer, Director)inAnkit Mahadevia(Founder)in
BoardBruce Booth(Director)inKees Been(Director)Samantha Singer(Director)
Co-investorsGV (Google Ventures)Hatteras Venture PartnersThird Point VenturesAtlas VentureRemeditex Ventures
Ronovo Surgical develops the Carina surgical robotics platform, including a vision system and instruments, for use by surgeons and hospitals.
HealthtechMedical DevicesRoboticsShanghai, CN
John Ma(Founder)inYing Mao(Founder)in
Co-investorsGranite AsiaINCE CapitalVivo CapitalLilly Asia Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Exits · 2
2 IPOsContineum TherapeuticsNASDAQ: CTNMProtagonist TherapeuticsNASDAQ: PTGX
Portfolio news
latest coverage across their companiesMestag · finsmes.com · Mar 17, 2026
PAQ Therapeutics · finsmes.com · Jan 26, 2026
Ronovo Surgical · finsmes.com · Sep 8, 2025
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Contineum Therapeutics | 7.1% | $16.00 | Apr 2024 | $26.7M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has JJDC made?
- JJDC has 14 tracked investments, 2 of which have exited, including 3 dated in the last 24 months.
- What stage does JJDC invest at?
- JJDC invests at the Seed, Series A, Series B stages.
- What is JJDC's typical check size?
- JJDC typically writes checks of $500K – $5M.
- What sectors does JJDC focus on?
- JJDC focuses on Biotech, Consumer, Healthtech, Medical Devices.
- Where is JJDC located?
- JJDC is headquartered in New Brunswick, US.
Similar investors
Korea Investment Partners is a South Korea-based venture capital firm that invests across multiple stages from early-stage startups through growth and buyout transactions, including venture debt and mezzanine financing. The firm operates across venture capital, middle market, and growth equity investment categories.
Fortune Venture Capital (Shenzhen Fortune Venture Capital Management Co., Ltd.) is a Chinese venture capital fund management company positioning itself as a long-term partner to entrepreneurs and a fund manager for investors.
Hiroshima Venture Capital Co. Ltd. is a Japanese venture capital firm that invests in and supports startups.
DC Investment Partners is a private fund that invests in early and growth stage companies with strong leadership, market traction, and a competitive edge, offering both capital and operational resources.